Lung Cancer | Specialty

Expert Outlines Opportunities With Osimertinib in EGFR-Mutant NSCLC

August 5th 2020

Elaine Shum, MD, sheds light on osimertinib as the standard of care in the frontline treatment of patients with EGFR-mutant non–small cell lung cancer, which may be on its way to becoming a key player in the adjuvant setting and a promising option to include with novel combinations.

Dr. Shum on Patient Consultation of Osimertinib in NSCLC

August 4th 2020

Elaine Shum, MD, discusses consulting patients with non-small cell lung cancer on the use of osimertinib.

Entrectinib Approved in Europe for NTRK+ Tumors and ROS1+ NSCLC

August 3rd 2020

The European Commission has approved entrectinib for the treatment of adult and pediatric patients ≥12 years of age with solid tumors that harbor an NTRK fusion, as well as for the treatment of adult patients with ROS1-positive, advanced non—small cell lung cancer not previously treated with ROS1 inhibitors.

KRAS G12C Inhibition in Advanced NSCLC: MRTX849

August 3rd 2020

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

August 3rd 2020

Development of KRAS G12C-Targeted Therapy in NSCLC

August 3rd 2020

Systemic Therapy for KRAS+ Advanced NSCLC

August 3rd 2020

Counseling Patients With NSCLC When KRAS is Detected

August 3rd 2020

Testing for KRAS Mutations in NSCLC

August 3rd 2020

KRAS Mutations in Solid Tumors

August 3rd 2020

Current Management of Oncogene-Driven NSCLC

August 3rd 2020

The Evolving Treatment Landscape in SCLC

July 31st 2020

Beth Sandy, MSN, CRNP, discusses the evolving treatment landscape in small cell lung cancer.

Dr. Sabari on Biomarkers of Response to Immunotherapy in Advanced NSCLC

July 31st 2020

Joshua K. Sabari, MD, discusses the need for additional biomarkers of response to immunotherapy in driver-negative advanced non–small cell lung cancer.

FDA Grants Adjuvant Osimertinib Breakthrough Status in Early-Stage EGFR+ NSCLC

July 30th 2020

The FDA has granted a breakthrough therapy designation to osimertinib for the adjuvant treatment of patients with stage IB, II, and IIIA EGFR-mutated non–small cell lung cancer following complete resection with curative intent.

Navigating New Immune-Based Combinations in Advanced NSCLC

July 29th 2020

Joshua K. Sabari, MD, discusses a number of immunotherapy regimens that have emerged in the frontline setting for patients with driver-negative advanced non–small cell lung cancer; however, for many patients, the decision comes down to pembrolizumab monotherapy or pembrolizumab in combination with platinum-doublet chemotherapy.

Savolitinib Granted Priority Review in China for METex14+ NSCLC

July 28th 2020

Hutchinson China Meditech Limited announces that The China National Medical Products Administration granted priority review to the new drug application for the MET inhibitor savolitinib for the treatment of patients with non–small cell lung cancer with MET exon 14 skipping mutations.

Poziotinib Yields Positive Results in HER2 Exon 20 Insertion–Mutated NSCLC

July 28th 2020

The phase 2 ZENITH20 trial evaluating poziotinib in previously treated patients with non–small cell lung cancer and HER2 exon 20 insertion mutations met its prespecified primary end point.

Dr. Bunn on Data With Trastuzumab Deruxtecan in HER2-Mutant NSCLC

July 27th 2020

Paul A. Bunn, Jr, MD, highlights encouraging data with fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

Dr. Chiang on Unanswered Questions With Immunotherapy in NSCLC

July 27th 2020

Anne Chiang, MD, PhD, discusses unanswered questions with immunotherapy in non–small cell lung cancer.

Lara Shares Updates With Immunotherapy in Extensive-Stage SCLC

July 27th 2020

Although platinum-based chemotherapy given concurrently with a PD-L1 inhibitor has become the standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer, investigators have found that maintenance immunotherapy and combination strategies have fallen short of expectations.